Latest Period
n/a
Security Snapshot
Korsana Biosciences, Inc. - Common Stock, no par value per share Institutional Ownership
CUSIP: 23255M303
13F Institutional Holders and Ownership History
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, no par value per share
- Shares outstanding
- 47,075,456
Key facts
- 23255M303 - Korsana Biosciences, Inc. - Common Stock, no par value per share is tracked under CUSIP 23255M303.
- Latest finished 13F holder period is not available.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Quarterly ownership records are not available yet for this CUSIP.
- This page updates as SEC-backed holdings history becomes available.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
23255M303
Latest holder period
n/a
13F holders
13D/G owners
4
CIK / CUSIP context first
23255M303 full holder history
Cyclerion Therapeutics, Inc. SEC filings
Cyclerion Therapeutics, Inc. company facts
Cyclerion Therapeutics, Inc. insider transactions
Broader feeds
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
23255M303
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 9,106,420 | Tomas Kiselak | 08 Sep 2026 | ||||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 4,552,277 | Venrock Healthcare Capital Partners III, L.P. | 08 Sep 2026 | ||||
| GENERAL ATLANTIC, L.P. | 6.8% | 3,201,131 | GENERAL ATLANTIC, L.P. | 08 Sep 2026 | ||||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 6.1% | 2,775,788 | Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 09 Sep 2026 |